This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Dr. Klaus Maleck

Chief Financial Officer ITM Group

Dr. Klaus Maleck joined ITM as Chief Financial Officer in June 2021. He has over 25 years of experience as a Biopharmaceutical Industry Executive.

Prior to joining ITM, he served as CEO of TETEC AG, a fully integrated regenerative medicine developer and manufacturer within the Aesculap/B Braun group, which grew under Klaus from 30 employees to one of the largest manufacturers in the field. This followed roles as CFO and CBO at Evotec AG, where he drove key corporate development events, including the Nasdaq listing of the company. Earlier in his career, Klaus was Co-Founder and CFO of BioGeneriX AG, the Biosimilars business of Ratiopharm, and a senior consultant to the life science industry with McKinsey & Co. He began his professional career as a Research Scientist at the Novartis Biotechnology and Genomics Center in NC (USA).

Klaus holds an MBA degree, as well as a master's degree in Biotechnology from the ESBS in Strasbourg (France), and a PhD in Biochemistry from the Max Planck Institute in Cologne (Germany).